Semaglutide shows strong weight loss results for adults over 65

हिंदी

A new analysis of clinical trials indicates that semaglutide, the active ingredient in Ozempic and Wegovy, helps older adults with obesity lose substantial weight and improve heart health markers. The findings come from data on participants aged 65 and above who received the once-weekly medication alongside lifestyle changes.

Researchers led by Prof Luca Busetto at the University of Padova examined results from the STEP 1, 3, 4, 5, 8 and 9 trials. The analysis focused on 358 adults aged 65 or older with obesity but without diabetes. Of these, 248 took semaglutide 2.4 mg while 110 received a placebo over 68 weeks.

संबंधित लेख

Elderly woman with type 2 diabetes walking healthily outdoors, holding semaglutide pen, with subtle ENDO 2026 study charts in background
AI द्वारा उत्पन्न छवि

Study presented at ENDO 2026 links semaglutide to fewer fractures in people with type 2 diabetes

AI द्वारा रिपोर्ट किया गया AI द्वारा उत्पन्न छवि तथ्य-जाँच किया गया

Semaglutide was associated with a lower rate of bone fractures and greater reductions in body mass index among adults with type 2 diabetes, according to a retrospective analysis presented at the Endocrine Society’s ENDO 2026 meeting in Chicago.

Study links Ozempic to lower depression and anxiety risks

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

AI द्वारा रिपोर्ट किया गया तथ्य-जाँच किया गया

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Health

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

Health

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Health

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Gut reset procedure limits weight regain after stopping Ozempic

A minimally invasive procedure called duodenal mucosal resurfacing may help patients maintain weight loss after discontinuing drugs like Ozempic and tirzepatide. Early results from the REMAIN-1 clinical trial show treated participants regained far less weight than those in a control group after six months off medication. The findings are set for presentation at Digestive Disease Week 2026.

Novo Nordisk heads to South African court over semaglutide copies

AI द्वारा रिपोर्ट किया गया

Danish drugmaker Novo Nordisk is taking a local compounding pharmacy to court in Pretoria to stop the sale of unregistered semaglutide products. The High Court application targets iDexis over patient safety concerns.

France reimburses Mounjaro and Wegovy for severe obesity

Starting this Monday, social security covers Mounjaro and Wegovy for patients with severe obesity or diabetes. It is a first in Europe.

17 जून 2026 22:43

Rutgers study finds GLP-1 drug use is tied to a weaker link between impulsivity and self-reported violence

16 जून 2026 07:37

Claims-data study finds many people with type 2 diabetes restart GLP-1 drugs after stopping

15 जून 2026 07:24

Oral GLP-1 pill shows strong results in diabetes trial

14 जून 2026 20:36

Study: Physical activity fell after some patients with obesity started GLP-1 drugs

06 जून 2026 09:59

Study links GLP-1 drugs to lower breast cancer risk

23 मई 2026 05:26

Analysis of FDA reports finds stronger safety signal for rare optic nerve injury with Wegovy than with Ozempic

08 मई 2026 00:46

Trojan horse obesity drug boosts weight loss in mice

05 मई 2026 14:05

Study finds people who use Ozempic-like drugs for weight loss face added stigma

25 अप्रैल 2026 05:27

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

09 अप्रैल 2026 23:54

Vanderbilt study finds muscle loss with weight loss drugs and surgery

यह वेबसाइट कुकीज़ का उपयोग करती है

हम अपनी साइट को बेहतर बनाने के लिए विश्लेषण के लिए कुकीज़ का उपयोग करते हैं। अधिक जानकारी के लिए हमारी गोपनीयता नीति पढ़ें।
अस्वीकार करें